Pharma Journalist -

GSK plc has agreed to acquire 35Pharma Inc., a privately held Canadian biopharmaceutical company focused on protein-based therapeutics. The deal brings into GSK’s pipeline HS235, an…
Read More...

Gilead Sciences, Inc. has entered into a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion, strengthening its oncology and cell therapy…
Read More...

AbbVie has unveiled plans to invest $380 million to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus, expanding…
Read More...

The U.S. Food and Drug Administration has released a new draft guidance aimed at accelerating the development and approval of highly targeted, individualized therapies for patients with…
Read More...

AstraZeneca has secured U.S. approval for a new all-oral, fixed-duration treatment regimen for adults with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL),…
Read More...

The European Commission has announced a €225 million investment aimed at accelerating the development of next-generation influenza vaccines capable of providing broader protection…
Read More...

AbbVie has announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for the combination of VENCLEXTA® (venetoclax) and acalabrutinib…
Read More...

Clinical-stage biotech VivaMed BioPharma has entered into a strategic partnership with Syngene International, a global contract research, development and manufacturing organization…
Read More...

Merck & Co., Inc., known as MSD outside the United States and Canada, has entered into a major research and development agreement with Mayo Clinic to apply artificial intelligence…
Read More...

Novartis has announced positive topline results from its pivotal Phase III RemIND trial evaluating oral remibrutinib in patients with chronic inducible urticaria (CIndU), a condition…
Read More...